Allosteric binding sites at the receptor–lipid bilayer interface: novel targets for GPCR drug discovery

Author(s):  
Ying Wang ◽  
Zhengtian Yu ◽  
Wen Xiao ◽  
Shaoyong Lu ◽  
Jian Zhang
Molecules ◽  
2021 ◽  
Vol 26 (3) ◽  
pp. 651
Author(s):  
Koji Umezawa ◽  
Isao Kii

Drug discovery using small molecule inhibitors is reaching a stalemate due to low selectivity, adverse off-target effects and inevitable failures in clinical trials. Conventional chemical screening methods may miss potent small molecules because of their use of simple but outdated kits composed of recombinant enzyme proteins. Non-canonical inhibitors targeting a hidden pocket in a protein have received considerable research attention. Kii and colleagues identified an inhibitor targeting a transient pocket in the kinase DYRK1A during its folding process and termed it FINDY. FINDY exhibits a unique inhibitory profile; that is, FINDY does not inhibit the fully folded form of DYRK1A, indicating that the FINDY-binding pocket is hidden in the folded form. This intriguing pocket opens during the folding process and then closes upon completion of folding. In this review, we discuss previously established kinase inhibitors and their inhibitory mechanisms in comparison with FINDY. We also compare the inhibitory mechanisms with the growing concept of “cryptic inhibitor-binding sites.” These sites are buried on the inhibitor-unbound surface but become apparent when the inhibitor is bound. In addition, an alternative method based on cell-free protein synthesis of protein kinases may allow the discovery of small molecules that occupy these mysterious binding sites. Transitional folding intermediates would become alternative targets in drug discovery, enabling the efficient development of potent kinase inhibitors.


Antibiotics ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 141
Author(s):  
Donatella Tondi

The spread of infections resistant to available anti-infective drugs is a serious menace to human health [...]


2021 ◽  
Vol 4 (2) ◽  
pp. 666-679
Author(s):  
Jiayin Diao ◽  
Aaron DeBono ◽  
Tracy M. Josephs ◽  
Jane E. Bourke ◽  
Ben Capuano ◽  
...  

2012 ◽  
Vol 82 (5) ◽  
pp. 843-859 ◽  
Author(s):  
Daniel C.-H. Lin ◽  
Qi Guo ◽  
Jian Luo ◽  
Jane Zhang ◽  
Kathy Nguyen ◽  
...  

2014 ◽  
Vol 86 (1) ◽  
pp. 116-123 ◽  
Author(s):  
Douglas A. Schober ◽  
Carrie H. Croy ◽  
Hongling Xiao ◽  
Arthur Christopoulos ◽  
Christian C. Felder

2012 ◽  
Vol 64 (2) ◽  
pp. 471-472
Author(s):  
Paulina Chorobik ◽  
Piotr Brański ◽  
Grzegorz Burnat ◽  
Barbara Chruścicka ◽  
Tomasz Lenda ◽  
...  

MedChemComm ◽  
2018 ◽  
Vol 9 (4) ◽  
pp. 606-613 ◽  
Author(s):  
Kristin K. Brown ◽  
Michael M. Hann ◽  
Ami S. Lakdawala ◽  
Rita Santos ◽  
Pamela J. Thomas ◽  
...  

The assessment of the suitability of novel targets to intervention by different modalities, e.g. small molecules or antibodies, is increasingly seen as important in helping to select the most progressable targets at the outset of a drug discovery project.


2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Tiffany Wu ◽  
Liskin Swint-Kruse ◽  
Aron W. Fenton

AbstractFor protein mutagenesis, a common expectation is that important positions will behave like on/off “toggle” switches (i.e., a few substitutions act like wildtype, most abolish function). However, there exists another class of important positions that manifests a wide range of functional outcomes upon substitution: “rheostat” positions. Previously, we evaluated rheostat positions located near the allosteric binding sites for inhibitor alanine (Ala) and activator fructose-1,6-bisphosphate (Fru-1,6-BP) in human liver pyruvate kinase. When substituted with multiple amino acids, many positions demonstrated moderate rheostatic effects on allosteric coupling between effector binding and phosphoenolpyruvate (PEP) binding in the active site. Nonetheless, the combined outcomes of all positions sampled the full range of possible allosteric coupling (full tunability). However, that study only evaluated allosteric tunability of “local” positions, i.e., positions were located near the binding sites of the allosteric ligand being assessed. Here, we evaluated tunability of allosteric coupling when mutated sites were distant from the allosterically-coupled binding sites. Positions near the Ala binding site had rheostatic outcomes on allosteric coupling between Fru-1,6-BP and PEP binding. In contrast, positions in the Fru-1,6-BP site exhibited modest effects on coupling between Ala and PEP binding. Analyzed in aggregate, both PEP/Ala and PEP/Fru-1,6-BP coupling were again fully tunable by amino acid substitutions at this limited set of distant positions. Furthermore, some positions exhibited rheostatic control over multiple parameters and others exhibited rheostatic effects on one parameter and toggle control over a second. These findings highlight challenges in efforts to both predict/interpret mutational outcomes and engineer functions into proteins.


Sign in / Sign up

Export Citation Format

Share Document